Related Experiment Videos
Cimetidine does not accelerate skin graft rejection in mice
Clinical and Experimental Immunology
|April 1, 1980
Summary
Cimetidine did not affect skin graft rejection in mice. This study found no significant difference in graft survival between cimetidine-treated mice and control groups, indicating no therapeutic benefit for this drug in preventing transplant rejection.
Area of Science:
- Immunology
- Transplantation Biology
- Pharmacology
Background:
- Skin graft rejection is a major challenge in transplantation.
- Understanding factors that modulate immune responses is crucial for improving graft survival.
- Cimetidine is a histamine-2 receptor antagonist with known immunomodulatory effects.
Purpose of the Study:
- To investigate the effect of cimetidine on the rejection of allogeneic and xenogeneic skin grafts.
- To determine if cimetidine administration influences graft survival times in a murine model.
Main Methods:
- Utilized a well-defined transplantation model in inbred mice.
- Studied four allogeneic and one xenogeneic skin graft combination.
- Administered cimetidine (25 mg/kg) intraperitoneally every 8 hours until graft rejection.
Main Results:
- No significant difference in skin graft survival was observed between cimetidine-treated groups and saline-treated control groups.
- Cimetidine did not prolong graft survival in any of the tested transplantation combinations.
Conclusions:
- Cimetidine does not appear to inhibit or delay skin graft rejection in this murine model.
- Further research is needed to explore other immunomodulatory strategies for preventing transplant rejection.